参麦注射液联合曲美他嗪片治疗甲状腺功能减退性心脏病的临床观察  

Clinical Observation of Shenmai Injection Combined with Trimetazidinee Tablet in the Treatment of Hypothyroid Heart Disease

作　　者：郭秀婷[1] 张芬[1] 裴玉梅[1] 

机构地区：[1]唐山市工人医院,河北唐山063000

出　　处：《中国药房》2015年第24期3329-3331,共3页China Pharmacy

基　　金：唐山市科学技术研究与发展计划项目(No.121302048a)

摘　　要：目的:观察参麦注射液联合曲美他嗪治疗甲状腺功能减退(以下简称"甲减")性心脏病的临床疗效及安全性。方法:64例甲减性心脏病患者随机均分为对照组和观察组。两组患者均给予常规治疗。在此基础上,对照组患者给予盐酸曲美他嗪片20 mg,口服,每日3次;观察组患者在对照组治疗的基础上给予参麦注射液40 ml静脉滴注,每日1次。两组患者疗程均为2个月。观察两组患者的临床疗效,治疗前后三碘甲腺原氨酸(T3)、甲状腺素(T4)、促甲状腺激素(TSH)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、心包积液深度及不良反应发生情况。结果:治疗后,观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。两组患者T3、T4均显著高于同组治疗前,TSH、LVESD均显著低于同组治疗前,但两组间比较差异均无统计学意义(P>0.05);两组患者LVEF显著高于同组治疗前,且观察组高于对照组,LVEDD、心包积液深度均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上,参麦注射液联合曲美他嗪治疗甲减性心脏病较单用曲美他嗪疗效更显著,安全性相当。OBJECTIVE： To observe the clinical efficacy and safety of Shenmai injection combined with Trimetazidinee tablet in the treatment of hypothyroid heart disease. METHODS： 64 patients with hypothyroid heart disease were randomly divided into control group and observation group. Patients in 2 groups were conventional treatment. Based on the treatment, control group was treated with Trimetazidine tablets 20 mg, orally, 3 times a day; based on the treatment in control group, observation group was ad- ditionally treated with Shenmai injection 40 ml by intravenous infusion, once a day. The treatment course was 2 months. The clinic data was observed, including clinical efficacy, and T3, T4, TSH, LVEF,LVEDD and LVESD before and after treatment, pericardial effusion depth and incidence of adverse reactions. RESULTS： The total effective rate in observation group was significantly higher than control group （P〈0.05）. After treatment, T3 and T4 in 2 groups were significantly higher than before, TSH and LVESD were significantly lower than before（P〈0.05）, however, the difference was not statistically significant between 2 groups （P〉0.05） ; LVEF in 2 groups was significantly higher than before, observation group was higher than control group, LVEDD and perieardial effusion depth were significantly lower than before, observation group was lower than control group （P〈0.05）. There were no obrious adverse reactions during treatment. CONCLUSIONS： Based on the conventional treatment, Shenmai injection combined with trimetazidinee has better efficacy tha,n only trimetazidinee in the treatment of hypothyroid heart disease, with similar safety.

关 键 词：参麦注射液 曲美他嗪 甲状腺功能减退性心脏病 疗效 安全性 

分 类 号：R453.9[医药卫生—治疗学]